Evidence map›Paper›PMID 31263265›Full record

ArticleNature cell biology2019

Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments.

Michalina Janiszewska, Doris P Tabassum, Zafira Castaño, Simona Cristea, Kimiyo N Yamamoto, Natalie L Kingston, Katherine C Murphy, Shaokun Shu, Nicholas W Harper, Carlos Gil Del Alcazar and 14 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Nature cell biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 109 papers.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 158 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Cancer, collapse, and the politics of somatic evolution.Evolution, medicine, and public health · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 2 countries.

Michalina JaniszewskaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8592-5146
Doris P TabassumDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Zafira CastañoDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
Simona CristeaDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kimiyo N YamamotoDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Natalie L KingstonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Katherine C MurphyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Shaokun ShuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nicholas W HarperDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Carlos Gil Del AlcazarDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Maša AlečkovićDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5653-8502
Muhammad B EkramDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ofir CohenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Minsuk KwakDepartment of Biomedical Engineering, Yale School of Medicine, New Haven, CT, USA.
Yuanbo QinDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
Tyler LaszewskiHematology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Adrienne LuomaDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, and Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, USA.
Andriy MarusykDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0087-9575
Kai W WucherpfennigDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, and Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, USA.
Nikhil WagleDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3332-9438
Rong FanDepartment of Biomedical Engineering, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0001-7805-8059
Franziska MichorDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4869-8842
Sandra S McAllisterDepartment of Medicine, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5111-5903
Kornelia PolyakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. kornelia_polyak@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-5964-0382
Brigham and Women's Hospital · USBroad Institute · USHarvard University · USDana-Farber Cancer Institute · USYale Cancer Center · USMedigene (Germany) · DEResearch Square (United States) · USScripps Research Institute · US

Funding

Targeting intratumor heterogeneity in breast cancerR35CA197623 · NCI · DANA-FARBER CANCER INST · PI KORNELIA POLYAK · 2015 to 2026
$12.4M
The Cell-Of-Origin of Human CancersU54CA143798 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI MICHOR, FRANZISKA · 2009 to 2014
$11.2M
Cancer Immunology Training GrantT32CA207021 · NCI · DANA-FARBER CANCER INST · PI WUCHERPFENNIG, KAI W · 2016 to 2020
$2.4M
Intratumor heterogeneity and therapeutic resistanceR00CA201606 · NCI · SCRIPPS FLORIDA · PI JANISZEWSKA, MICHALINA · 2018 to 2020
$852k
Intratumor heterogeneity and therapeutic resistanceK99CA201606 · NCI · DANA-FARBER CANCER INST · PI JANISZEWSKA, MICHALINA · 2016 to 2017
$252k
NCI NIH HHS K99 CA201606NCI NIH HHS R00 CA201606NCI NIH HHS R35 CA197623NCI NIH HHS T32 CA207021NCI NIH HHS U54 CA143798Swiss National Science Foundation 175139
6 · The paper itself

Abstract

Most human tumours are heterogeneous, composed of cellular clones with different properties present at variable frequencies. Highly heterogeneous tumours have poor clinical outcomes, yet the underlying mechanism remains poorly understood. Here, we show that minor subclones of breast cancer cells expressing IL11 and FIGF (VEGFD) cooperate to promote metastatic progression and generate polyclonal metastases composed of driver and neutral subclones. Expression profiling of the epithelial and stromal compartments of monoclonal and polyclonal primary and metastatic lesions revealed that this cooperation is indirect, mediated through the local and systemic microenvironments. We identified neutrophils as a leukocyte population stimulated by the IL11-expressing minor subclone and showed that the depletion of neutrophils prevents metastatic outgrowth. Single-cell RNA-seq of CD45

Indexed as

Tumor MicroenvironmentAnimalsBreast NeoplasmsCarcinogenesisDisease ProgressionHumansLungLung NeoplasmsMesenchymal Stem CellsNeoplasm MetastasisNeutrophils

Identifiers

PMID31263265
PMCPMC6609451
OpenAlexW2954031524

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.